Barclays’s Edesa Biotech EDSA Stock Holding History

Barclays’s Portfolio EDSA Stock Details EDSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6	Closed	-$14	–	5353
2025 Q3	$14	Buy	+6	New	+$14	﹤0.01%	5381
2021 Q4	–	Sell	-43	Closed	-$2K	–	4249
2021 Q3	$2K	Buy	+43	New	+$1.67K	﹤0.01%	4666

Other funds holding EDSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Barclays's EDSA Position: Q4 2025 in Review

Barclays sold out of Edesa Biotech (EDSA) in Q4 2025, closing a stake of 6 shares — an estimated $14 sold.

Barclays first reported a position in EDSA in Q3 2021 and held it in 2 quarters. The position peaked at $2K in Q3 2021. 22 funds tracked by Wall St. Rank hold EDSA as of Q4 2025.

Barclays reported no remaining Edesa Biotech position as of Q4 2025 after selling out during the quarter.
Barclays sold 6 Edesa Biotech shares in Q4 2025, an estimated $14.
Barclays first reported a position in Edesa Biotech in Q3 2021 and held it in 2 quarters.
Barclays's Edesa Biotech position peaked at $2K in Q3 2021.
22 funds tracked by Wall St. Rank held Edesa Biotech as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.